Opinion|Videos|February 6, 2025
Insights From SABCS 2024 and Future Directions in Breast Cancer
Author(s)Katherine Clifton, MD, Shipra Gandhi, MD
Dr. Gandhi and Dr. Clifton explore clinical decision-making and sequencing for selective estrogen receptor degraders (SERDs), antibody-drug conjugates (ADCs), and other targeted therapies in hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), balancing efficacy, safety, and patient characteristics, while highlighting promising data from the 2024 San Antonio Breast Cancer Symposium (SABCS) and the role of precision medicine in improving outcomes and patient experiences.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- When considering these SERD trials, emerging data with ADCs, and other targeted therapies (eg, inavolisib), how are you approaching clinical decision-making and sequencing in your patients?
- How do you anticipate sequencing SERDs in patients who may have received multiple prior lines of endocrine-based therapy?
- How do you envision optimally sequencing SERDs, ADCs, and other treatment options? How would you balance considerations about efficacy, safety, mechanism of action, and patient characteristics when determining the optimal treatment sequence?
- Please highlight the most exciting data or studies from SABCS that you find most promising in terms of improving outcomes in HR+/HER2– mBC.
- How has precision medicine improved outcomes and the patient experience from your perspective?
Advertisement
Related to this article
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Pembrolizumab for Unresectable/Metastatic TMB-H Solid Tumors
2
Experts Tackle Key Questions on CDK4/6 Inhibition Across HR+ Breast Cancer Settings
3
Pembrolizumab Plus Enfortumab Vedotin Earns EC Approval in Resectable MIBC
4
Dr Oberstein on the Rationale for Evaluating the PD-1/IL-15 Fusion Protein SAR445877 in MSS CRC
5